Skip to content

Addiction: all studies

Page 273 of 857: studies 2,721 to 2,730 of 8,563, newest first. Back to the addiction overview

Research

Impacto del uso recreativo de cannabis sobre las funciones ejecutivas de las personas jóvenes: una revisión sistemática

Revista de Ciencias Sociales August 5, 2025 Viriam Leiva Díaz, Beatriz Villalobos Núñez, Mariela Francine Rodríguez Valerio et al.

Chronic marijuana use has been linked to negative effects on executive functions, but there is uncertainty with recreational, sporadic, and non-dependent use. This article reports and analyzes the results of a systematic review of the evidence that has evaluated this issue specifically in young people. Only two studies that met the inclusion criteria were identified in the OVID, Embase and...

DOI: 10.15517/jtzqh419 (opens in new tab) Persona Developmental psychology Cartography

Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models

Frontiers in Systems Neuroscience August 5, 2025 Dotun Adeleye Adeyinka, Donelson R. Forsyth, Suzanne Currie et al. 7 citations

Psilocybin, a compound found in Psilocybe mushrooms, is emerging as a promising treatment for neurodegenerative and psychiatric disorders, including major depressive disorder. Its potential therapeutic effects stem from promoting neuroprotection, neurogenesis, and neuroplasticity, key factors in brain health. Psilocybin could help combat mild neurodegeneration by increasing synaptic density and...

Therapeutic and legal aspects of psilocybin in cancer-related depression

Frontiers in Psychiatry August 4, 2025 Wierzbicka Małgorzata, Renata Kopczyk, Alexander L. Gerlach et al. 1 citation

Depression prevalence is markedly elevated in oncological patients, particularly among head and neck cancer (HNC) cohorts, who face twice the prevalence of major depressive disorder (MDD) compared to other cancer populations. MDD in this context independently predicts poorer clinical outcomes and increased morbidity. HNC management often involves acute surgical interventions with disfiguring...

Ayahuasca-Induced Serotonin Syndrome: Risks, Mechanisms, and Clinical Considerations

Pharmaceutical Science August 1, 2025 Melissa Ortega

Ayahuasca is a traditional Amazonian brew composed primarily of Banisteriopsis caapi and Psychotria viridis, drawing increasing interest for its psychedelic effects and potential therapeutic applications. Its pharmacological action is based on the synergistic combination of β-carbolines (harmine, tetrahydroharmine, and harmaline), which act as reversible inhibitors of monoamine oxidase A...

Increased Mesostriatal Intrinsic Connectivity Associated With Cue Exposure in Adult Cannabis Users: Preliminary Findings.

Addiction Biology August 1, 2025 Natalia M Kleinhans, Garth E Terry, Dahyeon Kang et al.

Cue-induced craving-the desire to use a drug triggered by exposure to cues associated with prior use-is a central mechanism in the development and maintenance of problematic substance use behaviours. Drug cues have the power to induce craving even in long-term abstinent individuals, which has led clinicians to advise patients to avoid the people, places and objects that are associated with...

Impact of Nitrous Oxide on Neuropsychiatric Impairment in Adolescents: A Scoping Review.

Cureus August 1, 2025 Vanessa C Cornelio, Gary Lail, Kimberly Go et al.

Nitrous oxide (N₂O) misuse represents a growing public health issue, particularly among adolescents and young adults, who use it recreationally. This scoping review investigates recent and foundational studies on the long-term neuropsychiatric effects associated with prolonged and frequent use of this volatile gas. Various clinical databases and journal archives, such as those of the Journal of...

DOI: 10.7759/cureus.89448 (opens in new tab) Full text (opens in new tab) Addiction medicine Inhalant use disorder Nitrous oxide toxicity

Ketamine-Assisted Recovery (KARE): protocol for an open-label pilot trial of ketamine-assisted psychotherapy for publicly insured patients with methamphetamine use disorder and HIV risks

BMJ Open August 1, 2025 Nicky J. Mehtani, B. Anderson, Irina Alexander et al.

INTRODUCTION: Methamphetamine use disorder (MeUD) is a debilitating condition with no FDA-approved pharmacotherapies that has been associated with poor neurological, psychiatric and cardiovascular outcomes, particularly among low-income populations. The use of methamphetamine also increases risks for sexually transmitted infections (STIs) by reducing behavioural inhibitions while enhancing...

DOI: 10.1136/bmjopen-2025-100775 (opens in new tab) Ketamine Protocol science Methamphetamine Open label +3

The Effect of Ketamine on the Immune System in Patients with Treatment-Resistant Depression

International Journal of Molecular Sciences August 1, 2025 Łukasz P. Szałach, Klaudia Ciesielska-Figlon, A. Daca et al. 7 citations

Treatment-resistant depression (TRD) is associated with immune dysregulation. Ketamine, a rapid-acting antidepressant, may exert effects via immunomodulation. The aim was to examine ketamine’s impact on immune markers in TRD, including T-cell subsets, cytokines, and in vitro T-cell responses. Eighteen TRD inpatients received 0.5 mg/kg iv ketamine. Blood was sampled at baseline, 4 h, and 24 h to...

Psychedelics, Transformative Experience, and Modality An Analysis of Valid and Substantially Informed Consent in Psychedelic-assisted Therapy

Philosophy, Psychiatry, & Psychology August 1, 2025 David Zheng

Paul’s concepts of “Transformative Experiences” (TE) has sparked extensive discussion on multiple epistemological and ethical issues within philosophy. In particular, Paul’s work has inspired significant work on the possibility of informed consent with regard to medical interventions that may induce said TEs. One such intervention, namely Psychedelic-assisted Therapy (PAT), has been discussed...

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review.

Cureus August 1, 2025 Brett Hughes, Soz Mirza, Manasi Ponamala et al.

The stresses of the Coronavirus Disease of 2019 (COVID-19) pandemic highlighted the burden of psychiatric disorders within the pediatric population, revealing a pre-existing need for rapid-onset therapies that have since driven efforts to expand effective therapeutic interventions. In this narrative review, we utilized the Preferred Reporting Items for Systematic reviews and Meta-Analysis...